All updated as on -
By 2030, the market for nuclear medicine is anticipated to reach USD 24.9 billion, growing at a CAGR of 24.9% from 2023 to 2030.
Radiopharmaceuticals are essentially pharmaceutical preparations that contain radioactive isotopes that are employed in therapeutic and diagnostic procedures. They are small, straightforward compounds with radioactive properties that are utilised to treat neurological, cancerous, and cardiac conditions. Convenient therapeutic radiopharmaceuticals are used instead of traditional chemotherapy techniques for oncology and cancer treatment, which creates new business opportunities for radiopharmaceuticals.
The COVID 19 pandemic has had a substantial influence on the healthcare sector, notably leading to a reduction in inpatient and outpatient services for illnesses and the implementation of infection control and prevention strategies. For instance, the COVID 19 influence on Europe has impacted nuclear medicine education in the majority of countries, according to the study released in June 2022.
The industry is being significantly boosted by the increase in the incidence and prevalence of cancer and cardiovascular illnesses. Nuclear medicine is crucial since the majority of these cases could have been averted with the aid of improved identification and treatment. As nuclear medicine aids in the diagnosis and treatment of diseases, the rising prevalence of various disorders is anticipated to propel the expansion of the global nuclear medicine market during the course of the forecast year. Nuclear medicine is used to diagnose cancer and cardiovascular disease. Additionally, radiopharmaceuticals' application domains are expanding as a result of which their market share and demand are anticipated to increase over the course of the projection year.
Players may use this symptom to their advantage by providing radiopharmaceuticals for neurological purposes, so diversifying their product offers and market positioning. Its short shelf lives, hospital spending limitations, and expensive equipment are anticipated to impede the market's expansion. The largest influence on a radiopharmaceutical's shelf life, however, comes from the radioisotope's half-life and the radionuclide's chemical composition. Radiochemical purity is poor when radioisotopes are not used within the recommended shelf life because to radiation and chemical deterioration. This could be lethal during the course of treatment and diagnosis.
Report Coverage
Global Nuclear Medicine research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nuclear Medicine report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nuclear Medicine competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nuclear Medicine market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nuclear Medicine market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nuclear Medicine market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Nuclear Medicine market based on the below-mentioned segments:
Global Nuclear Medicine Market, By Product
Global Nuclear Medicine Market, By End User
Global Nuclear Medicine market, Regional Analysis
Radiopharmaceuticals are essentially pharmaceutical preparations that contain radioactive isotopes that are employed in therapeutic and diagnostic procedures. They are small, straightforward compounds with radioactive properties that are utilised to treat neurological, cancerous, and cardiac conditions. Convenient therapeutic radiopharmaceuticals are used instead of traditional chemotherapy techniques for oncology and cancer treatment, which creates new business opportunities for radiopharmaceuticals.
The COVID 19 pandemic has had a substantial influence on the healthcare sector, notably leading to a reduction in inpatient and outpatient services for illnesses and the implementation of infection control and prevention strategies. For instance, the COVID 19 influence on Europe has impacted nuclear medicine education in the majority of countries, according to the study released in June 2022.
The industry is being significantly boosted by the increase in the incidence and prevalence of cancer and cardiovascular illnesses. Nuclear medicine is crucial since the majority of these cases could have been averted with the aid of improved identification and treatment. As nuclear medicine aids in the diagnosis and treatment of diseases, the rising prevalence of various disorders is anticipated to propel the expansion of the global nuclear medicine market during the course of the forecast year. Nuclear medicine is used to diagnose cancer and cardiovascular disease. Additionally, radiopharmaceuticals' application domains are expanding as a result of which their market share and demand are anticipated to increase over the course of the projection year.
Players may use this symptom to their advantage by providing radiopharmaceuticals for neurological purposes, so diversifying their product offers and market positioning. Its short shelf lives, hospital spending limitations, and expensive equipment are anticipated to impede the market's expansion. The largest influence on a radiopharmaceutical's shelf life, however, comes from the radioisotope's half-life and the radionuclide's chemical composition. Radiochemical purity is poor when radioisotopes are not used within the recommended shelf life because to radiation and chemical deterioration. This could be lethal during the course of treatment and diagnosis.
Report Coverage
Global Nuclear Medicine research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nuclear Medicine report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nuclear Medicine competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nuclear Medicine market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Nuclear Medicine Market from 2021 to 2030.
- Market Forecast for Nuclear Medicine Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Nuclear Medicine competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Nuclear Medicine
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nuclear Medicine market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nuclear Medicine market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group
Primary Target Market
- Market Players of Nuclear Medicine
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Nuclear Medicine market based on the below-mentioned segments:
Global Nuclear Medicine Market, By Product
- Diagnostic Products
- Therapeutic Products
Global Nuclear Medicine Market, By End User
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Others
Global Nuclear Medicine market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive nuclear medicine market market research and competitor analysis for your business to help you develop more profound insights into the nuclear medicine market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the nuclear medicine market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.